Phaseline

Targets › NRAS

NRAS (GTPase NRas): drug programs, companies and trials

10 programs from 9 companies in 13 trials: 12 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.

Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. (UniProt, P01111)

Open in Phaseline: the race on NRAS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Guangzhou JOYO PharmaJYP0015
Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS
KRAS, NRAS, HRASPhase 2Solid TumorDec 2026
Elicio TherapeuticsELI-002 7P
Lipid-conjugated CpG oligonucleotide (Amph-CpG-7909) plus lipid-conjugated peptide-based a
KRAS, NRASPhase 1Pancreatic Ductal Adenocarcinoma; Pancreatic CancerNov 2026
Oslo University HospitalTG01/QS-21
KRAS/NRAS mutation-specific peptide vaccine with QS-21 adjuvant
KRAS, NRASPhase 1Multiple MyelomaMay 2027
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)BBO-10203
PI3Kα:RAS breaker
PIK3CA, KRAS, NRAS, HRASPhase 1Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung CancerAug 2027
Adlai Nortye BiopharmaAN9025
Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R
KRAS, NRAS, HRASPhase 1Solid Tumors (Phase 1)Jan 2028
Institut de Recherches Internationales ServierS241656
RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III)
BRAF, CRAF, KRAS, NRASPhase 1Non-small Cell Lung CancerJun 2028
Adlai Nortye BiopharmaAN4035
CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload
CEACAM5, KRAS, NRAS, HRASPhase 1Solid Tumor (Phase I)Dec 2028
Relay TherapeuticsRLY-8161
NRAS-selective inhibitor
NRASPhase 1Advanced NRAS-Mutant MelanomaMay 2029
Memorial Sloan Kettering Cancer CenterMSK-TCR5
T cell receptor (TCR) engineered to recognize RAS G12D mutations
KRAS, HRAS, NRASPhase 1Solid TumorJun 2030
Shanghai YingLi PharmaceuticalYL-17231
Pan-RAS inhibitor
KRAS, HRAS, NRASPhase 1Advanced Solid Tumors–

Conditions

Non-small Cell Lung Cancer (2) Solid Tumor (2) Non-Small Cell Lung Cancer (1) Solid Tumor, Adult (1) Pancreatic Ductal Adenocarcinoma (1) Pancreatic Cancer (1) Solid Tumors (Phase 1) (1) Advanced NRAS-Mutant Melanoma (1) Advanced Solid Tumors (1) Solid Tumor (Phase I) (1) Multiple Myeloma (1)

Modalities

small molecule (6), mixed (2), protein or peptide (2)

Companies

Adlai Nortye Biopharma (2) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) Guangzhou JOYO Pharma (1) Elicio Therapeutics (1) Relay Therapeutics (1) Institut de Recherches Internationales Servier (1) Shanghai YingLi Pharmaceutical (1) Oslo University Hospital (1) Memorial Sloan Kettering Cancer Center (1)

Related targets

KRAS (9) HRAS (6) PIK3CA (1) BRAF (1) CRAF (1) CEACAM5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.